64 results on '"Grembiale, R. D."'
Search Results
2. AB0656 Carotid Intima-media thickness as potential marker of cardiovascular risk in systemic sclerosis: a cross-sectional study.
- Author
-
Iaquinta, F. S., primary, Di Napoli, S., additional, Grosso, R., additional, Naty, S., additional, Cassano, V., additional, Crescibene, D., additional, Armentaro, G., additional, Sciacqua, A., additional, and Grembiale, R. D., additional
- Published
- 2022
- Full Text
- View/download PDF
3. AB0861-HPR MENTAL DISORDERS AND GASTROINTESTINAL SYMPTOMS IN RHEUMATIC DISEASES: A CROSS-SECTIONAL STUDY
- Author
-
Iaquinta, F. S., primary, Spagnuolo, R., additional, Naty, S., additional, Doldo, P., additional, and Grembiale, R. D., additional
- Published
- 2021
- Full Text
- View/download PDF
4. POS1457-HPR GASTROINTESTINAL SYMPTOMS AND RHEUMATIC DISEASES: TWO SIDES OF THE SAME COIN
- Author
-
Spagnuolo, R., primary, Iaquinta, F. S., additional, Naty, S., additional, Grembiale, R. D., additional, and Doldo, P., additional
- Published
- 2021
- Full Text
- View/download PDF
5. AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: RESULTS AT 3 MONTHS FROM THE GO-BEYOND ITALY STUDY
- Author
-
D’angelo, S., primary, Tirri, E., additional, Giardino, A. M., additional, Matucci-Cerinic, M., additional, Dagna, L., additional, Santo, L., additional, Ciccia, F., additional, Frediani, B., additional, Govoni, M., additional, Bobbio Pallavicini, F., additional, Grembiale, R. D., additional, Delle Sedie, A., additional, Cercone, S., additional, Mule’, R., additional, Cantatore, F. P., additional, Foti, R., additional, Gremese, E., additional, Perricone, R., additional, Salaffi, F., additional, Viapiana, O., additional, Cauli, A., additional, Giacomelli, R., additional, Arcarese, L., additional, Guggino, G., additional, Russo, R., additional, Capocotta, D., additional, Nacci, F., additional, Anelli, M. G., additional, Picerno, V., additional, and Iannone, F., additional
- Published
- 2021
- Full Text
- View/download PDF
6. POS1061 THE ITALIAN PROSPECTIVE SIRENA STUDY: FOCUS ON EARLY PSORIATIC ARTHRITIS COHORT AND GENDER DIFFERENCES
- Author
-
Zabotti, A., primary, Luchetti, M. M., additional, Selmi, C., additional, Ramonda, R., additional, Grembiale, R. D., additional, Dagna, L., additional, D’angelo, S., additional, Cafaro, G., additional, De Vita, S., additional, Felicetti, M., additional, Marelli, S., additional, Frigerio, D., additional, and Favalli, E., additional
- Published
- 2021
- Full Text
- View/download PDF
7. AB0680 BASELINE CHARACTERISTICS OF PATIENTS ENROLLED IN THE ONGOING SIRENA STUDY, A NATIONAL PROSPECTIVE OBSERVATIONAL REGISTRY IN SPONDYLOARTHRITIS SUBJECTS
- Author
-
Zabotti, A., primary, Gabrielli, A., additional, Selmi, C., additional, Grembiale, R. D., additional, Ramonda, R., additional, Dagna, L., additional, D’angelo, S., additional, Gerli, R., additional, De Vita, S., additional, Marelli, S., additional, Frigerio, D., additional, and Favalli, E., additional
- Published
- 2020
- Full Text
- View/download PDF
8. THU0618-HPR PSYCHOSOCIAL CHANGES IN RHEUMATIC DISEASE: A NURSING LED CROSS-SECTIONAL STUDY
- Author
-
Spagnuolo, R., primary, Grembiale, R. D., additional, Iaquinta, F. S., additional, Funari, V., additional, Pagnotta, R., additional, Naty, S., additional, and Doldo, P., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data
- Author
-
D Angelo, S., Gilio, M., D Attino, R. M., Gualberti, G., Merolla, R., Di Luzio Paparatti, U., Malavolta, N., Corvaglia, S., Marchetta, A., Scambi, C., Romeo, N., Pettiti, G., Salvarani, C., Catanoso, M. G., Scarpa, R., Costa, L., Ramonda, R., Frallonardo, P., Muratore, M., Quarta, L., Passiu, G., Erre, G. L., Lubrano, D., Tirri, E., Govoni, M., Furini, F., Russo, R., Buono, R., Pozzi, M. R., Riva, M., Grembiale, R. D., Caterina Bruno, Gibertini, P., Marchesoni, A., D'Angelo, Salvatore, Gilio, Michele, D'Attino, Rita M, Gualberti, Giuliana, Merolla, Rocco, di Luzio Paparatti, Umberto, Malavolta, Nazzarena, Corvaglia, Stefania, Marchetta, Antonio, Scambi, Cinzia, Romeo, Nicoletta, Pettiti, Giorgio, Salvarani, Carlo, Catanoso, Maria Grazia, Scarpa, Raffaele, Costa, Luisa, Ramonda, Roberta, Frallonardo, Paola, Muratore, Maurizio, Quarta, Laura, Passiu, Giuseppe, Erre, Gian Luca, Lubrano, Daniele, Tirri, Enrico, Govoni, Marcello, Furini, Federica, Russo, Romualdo, Buono, Rosario, Pozzi, Maria Rosa, Riva, Marta, Grembiale, Rosa Daniela, Bruno, Caterina, Gibertini, Patrizia, and Marchesoni, Antonio
- Subjects
Ankylosing ,Adult ,Male ,ankylosing spondylitis, non-radiographic axial spondyloarthritis, quality of life, epidemiology, Italy ,Anti-Inflammatory Agents ,Socio-culturale ,Young Adult ,ankylosing spondylitis ,Spondylarthritis ,Humans ,Spondylitis, Ankylosing ,Prospective Studies ,Spondylarthriti ,Anti-Inflammatory Agents, Non-Steroidal ,Antirheumatic Agent ,Middle Aged ,Prospective Studie ,Italy ,Antirheumatic Agents ,Quality of Life ,non-radiographic axial spondyloarthritis ,epidemiology ,Female ,Non-Steroidal ,Spondylitis ,Human - Abstract
To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting.QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA.Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup.QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.
- Published
- 2018
10. Effects of immunotherapy on bronchial reactivity in allergic rhinitics with bronchial hyperresponsiveness
- Author
-
Grembiale, R. D., Naty, S., Camporota, L., and Tranfa, C.M.E.
- Published
- 1998
11. Snail Ingestion and Asthma
- Author
-
GREMBIALE, R. D., NATY, S., PELAIA, G., TRANFA, C. M. E., and MARSICO, S. A.
- Published
- 1996
12. Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis
- Author
-
Ursini F., Russo E., Hribal M. L., Mauro D., Savarino F., Bruno C., Tripolino C., Rubino M., Naty S., Grembiale R. D., Ursini, F., Russo, E., Hribal, M. L., Mauro, D., Savarino, F., Bruno, C., Tripolino, C., Rubino, M., Naty, S., Grembiale, R. D., Ursini F., Russo E., Hribal M.L., Mauro D., Savarino F., Bruno C., Tripolino C., Rubino M., Naty S., and Grembiale R.D.
- Subjects
Regulatory t-cells ,adipose-tissue inflammation ,receptor kinase 2 ,metabolic syndrome ,cardiovascular risk ,accelerated atherosclerosis ,diabetes-mellitus ,american-college ,disease-activity ,resistance ,NO - Abstract
Rheumatoid arthritis (RA) is characterized by increased insulin resistance, a well-known risk factor for diabetes and cardiovascular diseases. The aim of the present study was to evaluate the effect of abatacept on insulin sensitivity in RA patients with moderate to severe disease despite treatment with methotrexate. Fifteen RA patients were recruited for the present study. Patients were evaluated at time 0 and after 6 months of the treatment with i.v. abatacept at the dosage recommended for weight range. Evaluation included oral glucose tolerance test (OGTT) at both time points. Insulin sensitivity was estimated with insulin sensitivity index (ISI) by Matsuda, a measure of whole-body insulin sensitivity. ISI significantly increased after the treatment with abatacept from 3.7±2.6 to 5.0±3.2 (P=0.003) with a mean difference of 1.23. Analysis of glucose and insulin values during OGTT revealed a reduction of both glucose (303.9±73.4mg/dLmin versus 269.2±69.5mg/dLmin, P=0.009) and insulin (208.4±119.7mg/dLmin versus 158.0±95.3mg/dLmin, P=0.01) area under the curves (AUCs). Accordingly also glycated hemoglobin significantly improved (5.5±0.4% versus 5.3±0.3%, P=0.04). No significant differences were found for measures of β-cell function insulinogenic index (1.11±1.19 versus 1.32±0.82, P=0.77) and oral disposition index (2.0±5.4 versus 6.0±6.0, P=0.25). Treatment with abatacept seems to be able to improve whole-body insulin sensitivity in RA patients without affecting β-cell function.
- Published
- 2015
13. Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case–control study.
- Author
-
Prete, M., Favoino, E., Giacomelli, R., Afeltra, A., Cantatore, F. P., Bruno, C., Corrado, A., Emmi, L., Emmi, G., Grembiale, R. D., Navarini, L., Marcoccia, A., Liakouli, V., Riccardi, A., Valentini, G., and Perosa, F.
- Subjects
RAYNAUD'S disease ,SOCIAL influence ,CASE-control method ,CONTACT lenses ,HABIT ,CONNECTIVE tissues - Abstract
Raynaud's phenomenon (RP) is a clinical disorder characterized by recurrent, reversible episodes of digital vasospasm. RP can be classified as primary (pRP) or secondary, depending on whether it occurs as a benign condition (not disease-associated) or is associated with other diseases, mainly of the connective tissues. In both cases, it can be triggered by environmental factors, as indicated by the increased incidence of pRP episodes following exposure to cold, vibration injury or chemicals. The purpose of this prospective case–control study was to assess, in an Italian cohort of 132 pRP patients, the association of the phenomenon with demographic, lifestyle habits, environmental and work-related factors. Compared to healthy controls, pRP was found to be inversely associated with the use of contact lenses (OR = 0.4; p = 0.004) and of chlorous-based disinfectants (OR = 0.3; p < 0.001) and directly associated with the presence of prosthesis implants (OR = 5.3; p = 0.001) and the use of hydrogen peroxide-based compounds (OR = 2.6; p = 0.002), suggesting that the latter should be avoided in RP affected patients. Multivariate and multivariable analysis confirmed the associations. Further investigations are needed to understand the mechanism(s) underlying these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. DISEASE COURSE AND PREDICTORS FOR ACHIEVING 6-MONTH MINIMAL DISEASE ACTIVITY IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS FROM THE ITALIAN PROSPECTIVE SIRENA STUDY.
- Author
-
Zabotti, A., Luchetti, M. M., Selmi, C., Ramonda, R., Grembiale, R. D., D'angelo, S., Marelli, S., and Favalli, E.
- Published
- 2023
- Full Text
- View/download PDF
15. Kaposi's sarcoma after T-cell costimulation blockade with abatacept in rheumatoid arthritis: a case report
- Author
-
Olivo, D., primary, Grembiale, R. D., additional, Tallarigo, F., additional, Russo, E., additional, De Sarro, G., additional, and Ursini, F., additional
- Published
- 2017
- Full Text
- View/download PDF
16. A single blind, partial crossover clinical trial of the effects of inhaled fluticasone propionate and nedocromil sodium on airway hyperresponsiveness to methacholine
- Author
-
VATRELLA, ALESSANDRO, PELAIA G., PARRELLA R., LEMBO L. M., GREMBIALE R. D., SOFIA M., MARSICO S. A., Vatrella, Alessandro, Pelaia, G., Parrella, R., Lembo, L. M., Grembiale, R. D., Sofia, M., and Marsico, S. A.
- Published
- 2002
17. Aspetti funzionali nell’asma bronchiale
- Author
-
TRANFA, Carmelindo Mario Enrico, GREMBIALE R. D., VATRELLA A., Tranfa, Carmelindo Mario Enrico, Grembiale, R. D., and Vatrella, A.
- Published
- 1999
18. I corticosteroidi per via inalatoria
- Author
-
MARSICO S. A., PELAIA G., GREMBIALE R. D., TRANFA, Carmelindo Mario Enrico, Marsico, S. A., Tranfa, Carmelindo Mario Enrico, Pelaia, G., and Grembiale, R. D.
- Published
- 1994
19. Calcium Ions and Airway Smooth Muscle Contraction
- Author
-
Marsico, S. A., primary, Pelaia, G., additional, Grembiale, R. D., additional, Pugliese, C., additional, and Cellamare, P., additional
- Full Text
- View/download PDF
20. Oxidative stress and lung diseases
- Author
-
Maselli, R., Grembiale, R. D., Pelaia, G., and Giovanni Cuda
- Subjects
Lung Diseases ,Mitogen-Activated Protein Kinase Kinases ,Oxidative Stress ,Humans ,Signal Transduction - Abstract
Several different lung diseases are characterized by an oxidant/antioxidant imbalance, which is a major cause of cell damage. Oxidative stress activates a complex network of intracellular signal transduction pathways involved in the regulation of transcription factors such as nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1). Within this context, a key role is played by mitogen-activated protein kinases (MAPK), which are highly expressed by pulmonary endothelial and airway epithelial cells. By exposing these cell lines to oxidant agents, our group has shown that oxidative stress leads to a significant MAPK activation, which can be effectively inhibited by corticosteroids. We believe that studies such as ours may contribute to further elucidate the molecular events underlying the therapeutic action of these drugs in many respiratory disorders caused by oxidative/proinflammatory pathogenic mechanisms. In addition, our findings may help to unveil new anti-oxidant treatments based on MAPK modulation.
- Published
- 2003
21. AB0489 Correlation between vestibular function and raynaud’s phenomenon
- Author
-
Bruno, C., primary, Petrolo, C., additional, Grembiale, A., additional, Naty, S., additional, Chiarella, G., additional, and Grembiale, R. D., additional
- Published
- 2013
- Full Text
- View/download PDF
22. AB0724 Glucose metabolism disturbances in never treated inflammatory arthritis patients.
- Author
-
Ursini, F., primary, Grembiale, A., additional, Gagliardi, D., additional, Savarino, F., additional, Calabria, M., additional, Naty, S., additional, and Grembiale, R. D., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
- Author
-
Pelaia, G., Gallelli, L., Romeo, P., Renda, T., Busceti, M.T., Proietto, A., Grembiale, R. D., Marsico, S. A., Maselli, R., and Vatrella, A.
- Published
- 2011
- Full Text
- View/download PDF
24. Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease
- Author
-
Pelaia, G., Gallelli, L., Vatrella, A., Grembiale, R. D., Maselli, R., Sarro, G. B. De, and Marsico, S. A.
- Published
- 2002
- Full Text
- View/download PDF
25. Effects of glucocorticoids on activation of c-jun N-terminal, extracellular signal-regulated, and p38 MAP kinases in human pulmonary endothelial cells
- Author
-
Pelaia, G., Cuda, G., Vatrella, A., Grembiale, R. D., Sarro, G. De, Maselli, R., Costanzo, F. S., Avvedimento, V. E., Rotiroti, D., and Marsico, S. A.
- Published
- 2001
- Full Text
- View/download PDF
26. Basi fisiopatologiche della terapia del broncospasmo
- Author
-
VATRELLA A., PELAIA G., MATTIELLO A., GREMBIALE R. D., MARSICO S. A, BARIFFI F., TRANFA, Carmelindo Mario Enrico, Vatrella, A., Pelaia, G., Mattiello, A., Grembiale, R. D., Tranfa, Carmelindo Mario Enrico, Marsico, S. A., and Bariffi, F.
- Published
- 1989
27. SUDDEN PROGRESSION FROM IMPAIRED GLUCOSE TOLERANCE TO TYPE 2 DIABETES AFTER DISCONTINUATION OF ADMINISTRATION OF ANTI-TUMOR NECROSIS FACTOR-ALPHA ANTIBODY INFLIXIMAB.
- Author
-
Ursini, F., Succurro, E., Grembiale, A., Rudi, S., Grembiale, R. D., and Arturi, F.
- Published
- 2010
- Full Text
- View/download PDF
28. Chronic obstructive pulmonary disease (COPD) treatment in the elderly.
- Author
-
Grembiale, R. D., Naty, S., and Ursini, F.
- Subjects
OBSTRUCTIVE lung disease treatment ,OLDER patients ,NUTRITIONAL assessment ,MENTAL health ,MORTALITY ,BIOTECHNOLOGY - Abstract
The article discuses various aspects related to the treatment of elderly people suffering from Chronic obstructive pulmonary disease (COPD). As stated, COPD is a very common disease among elderly and is an important cause of morbidity and mortality. The treatment of elderly patients with COPD should include a multidisciplinary approach. In addition to the assessment of lung ventilatory performance and functional impairment, their nutritional status and mental health should also be evaluated.
- Published
- 2010
- Full Text
- View/download PDF
29. To Supplement or not to Supplement? The Rationale of Vitamin D Supplementation in Systemic Lupus Erythematosus
- Author
-
Daniele Mauro, Myles Lewis, Michele Gilio, Rosa Daniela Grembiale, Alessandra Nerviani, Nerviani, A., Mauro, D., Gilio, M., Grembiale, R. D., and Lewis, M. J.
- Subjects
030203 arthritis & rheumatology ,0301 basic medicine ,Lupu ,Systemic lupus erythematosus ,Vitamin d supplementation ,Supplementation ,business.industry ,medicine.disease ,Disease activity ,03 medical and health sciences ,Immune system ,030104 developmental biology ,0302 clinical medicine ,Rheumatology ,immune system diseases ,Immunology ,Vitamin D and neurology ,Medicine ,Vitamin D ,skin and connective tissue diseases ,business ,Erythematosu - Abstract
Background: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal activation of the immune system, chronic inflammation and organ damage. Lupus patients are more prone to be vitamin D deficient. However, current evidence is not conclusive with regards to the role played by vitamin D in SLE development, progression, and clinical manifestations. Objective: Here, we will summarise the current knowledge about vitamin D deficiency prevalence, risk factors, molecular effects, and potential pathogenic role in SLE. We will focus on the link between vitamin D deficiency and lupus clinical manifestations, and on the clinical trials assessing the effects of vitamin D supplementation in SLE. Method: A detailed literature search was performed exploiting the available databases, using “vitamin D and lupus/SLE” as keywords. The relevant interventional trials published over the last decade have been considered and the results are reported here. Conclusion: Several immune cells express vitamin D receptors. Thus, an immunomodulatory role for vitamin D in lupus is plausible. Numerous observational studies have investigated the relationship between vitamin D levels and clinical/serological manifestations of SLE with contrasting results. Negative correlations between vitamin D levels and disease activity, fatigue, renal and cardiovascular disease, and anti-dsDNA titres have been described but not conclusively accepted. In experimental models of lupus, vitamin D supplementation can improve the disease. Interventional trials have assessed the potential therapeutic value of vitamin D in SLE, but further larger studies are needed.
- Published
- 2018
30. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus
- Author
-
Giacomelli, Roberto, Afeltra, Antonella, Bartoloni, Elena, Berardicurti, Onorina, Bombardieri, Michele, Bortoluzzi, Alessandra, Carubbi, Francesco, Caso, Francesco, Cervera, Ricard, Ciccia, Francesco, Cipriani, Paola, Coloma-Bazán, Emmanuel, Conti, Fabrizio, Costa, Luisa, D'Angelo, Salvatore, Distler, Oliver, Feist, Eugen, Foulquier, Nathan, Gabini, Marco, Gerber, Vanessa, Gerli, Roberto, Grembiale, Rosa Daniela, Guggino, Giuliana, Hoxha, Ariela, Iagnocco, Annamaria, Jordan, Suzana, Kahaleh, Bashar, Lauper, Kim, Liakouli, Vasiliki, Lubrano, Ennio, Margiotta, Domenico, Naty, Saverio, Navarini, Luca, Perosa, Federico, Perricone, Carlo, Perricone, Roberto, Prete, Marcella, Pers, Jacques-Olivier, Pitzalis, Costantino, Priori, Roberta, Rivellese, Felice, Ruffatti, Amelia, Ruscitti, Piero, Scarpa, Raffaele, Shoenfeld, Yehuda, Triolo, Giovanni, Tzioufas, Athanasios, D’Angelo, Salvatore, Giacomelli, Roberto, Afeltra, Antonella, Bartoloni, Elena, Berardicurti, Onorina, Bombardieri, Michele, Bortoluzzi, Alessandra, Carubbi, Francesco, Caso, Francesco, Cervera, Ricard, Ciccia, Francesco, Cipriani, Paola, Coloma-Bazán, Emmanuel, Conti, Fabrizio, Costa, Luisa, D'Angelo, Salvatore, Distler, Oliver, Feist, Eugen, Foulquier, Nathan, Gabini, Marco, Gerber, Vanessa, Gerli, Roberto, Grembiale, Rosa Daniela, Guggino, Giuliana, Hoxha, Ariela, Iagnocco, Annamaria, Jordan, Suzana, Kahaleh, Bashar, Lauper, Kim, Liakouli, Vasiliki, Lubrano, Ennio, Margiotta, Domenico, Naty, Saverio, Navarini, Luca, Perosa, Federico, Perricone, Carlo, Perricone, Roberto, Prete, Marcella, Pers, Jacques-Olivier, Pitzalis, Costantino, Priori, Roberta, Rivellese, Felice, Ruffatti, Amelia, Ruscitti, Piero, Scarpa, Raffaele, Shoenfeld, Yehuda, Triolo, Giovanni, Tzioufas, Athanasios, Clinical Unit of Rheumatology, L'Aquila, Università Campus Bio-Medico di Roma / University Campus Bio-Medico of Rome ( UCBM), Department of Medicine [Perugia, Italy] (Rheumatology, Unit), Università degli Studi di Perugia (UNIPG), The London School of Medicine & Dentistry, Queen Mary University London, London, UK, Sant'Anna University Hospital, Partenaires INRAE, University of L'Aquila [Italy] (UNIVAQ), 'Federico II' University of Naples Medical School, Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain, Department of Medicine, Universitat Autonòma, Barcelona, University of the Study of Campania Luigi Vanvitelli, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Hospital Clínico San Carlos [Madrid, Spain], Department of Rheumatology [Zürich], Balgrist University Hospital, Helios Department of Rheumatology, Sophie-v.-Boetticher-Straße 1, 39245 Gommern, Germany, Laboratoire de Traitement de l'Information Medicale (LaTIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), UOC Reumatologia, Presidio Ospedaliero 'Santo Spirito', Pescara, Italy, University hospital of Zurich [Zurich], University of Perugia, University of Catanzaro, University of Palermo, Italy, San Bortolo Hospital, University of Padova [Padova, Italy], Rheumatology Unit, Torino, Department of Chemistry, University of Toledo, University of Toledo, Division of Rheumatology [Geneva, Switzerland], Geneva University Hospital, Geneva-Department of Internal Medicine [Genève], University of Barcelona, University of Molise [Campobasso] (UNIMOL), University of Molise, Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy., Università degli studi di Bari Aldo Moro (UNIBA), University of Rome TorVergata, LabEX IGO Immunothérapie Grand Ouest, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Queen Mary University of London, Barts and The London School of Medicine and Dentistry, School of Medicine and Dentistry, Queen Mary University of London, Institute of cancer, Department of Medicine (DIMED), University of Naples Federico II, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University [Tel Aviv], Sechenov First Moscow State Medical University, Università degli studi di Palermo - University of Palermo, National and Kapodistrian University of Athens (NKUA), Department of Pathophysiology, Medical School, University of Athens, Giacomelli, R., Afeltra, A., Bartoloni, E., Berardicurti, O., Bombardieri, M., Bortoluzzi, A., Carubbi, F., Caso, F., Cervera, R., Ciccia, F., Cipriani, P., Coloma-Bazan, E., Conti, F., Costa, L., D'Angelo, S., Distler, O., Feist, E., Foulquier, N., Gabini, M., Gerber, V., Gerli, R., Grembiale, R. D., Guggino, G., Hoxha, A., Iagnocco, A., Jordan, S., Kahaleh, B., Lauper, K., Liakouli, V., Lubrano, E., Margiotta, D., Naty, S., Navarini, L., Perosa, F., Perricone, C., Perricone, R., Prete, M., Pers, J. -O., Pitzalis, C., Priori, R., Rivellese, F., Ruffatti, A., Ruscitti, P., Scarpa, R., Shoenfeld, Y., Triolo, G., and Tzioufas, A.
- Subjects
0301 basic medicine ,rheumatoid arthritis ,medicine.medical_specialty ,antiphospholipid syndrome ,precision medicine ,primary sjogren's syndrome ,spondyloarthritides ,systemic lupus erythematosus ,systemic sclerosis ,consensus ,humans ,autoimmune diseases ,lupus erythematosus, systemic ,sjogren's syndrome ,Consensus ,spondyloarthritide ,Immunology ,systemic lupus erythematosu ,Sjogren's Syndrome ,Context (language use) ,Consensu ,primary Sjogren's syndrome ,Autoimmune Disease ,Treatment failure ,Autoimmune Diseases ,NO ,Efficacy ,03 medical and health sciences ,0302 clinical medicine ,primary Sjogren’s syndrome ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,Immunology and Allergy ,Humans ,Lupus Erythematosus, Systemic ,In patient ,Intensive care medicine ,Adverse effect ,030203 arthritis & rheumatology ,business.industry ,Precision medicine ,Environmental exposure ,rheumatoid arthriti ,medicine.disease ,3. Good health ,030104 developmental biology ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,systemic sclerosi ,Human - Abstract
International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. In this work, the growing body of evidence is summarized regarding the predictive factors for drug response in patients with AIDs, applying the precision medicine principles to provide high-quality evidence for therapeutic opportunities in improving the management of these patients.
- Published
- 2021
31. Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients
- Author
-
Francesco Ciccia, Federico Perosa, Giacomo Emmi, Antonio Barile, Giuliana Guggino, Francesco Caso, Piero Ruscitti, Raffaele Scarpa, Roberto Giacomelli, Rosa Daniela Grembiale, Vasiliki Liakouli, Francesco Paolo Cantatore, Onorina Berardicurti, Daniela Iacono, Ilenia Pantano, Paola Cipriani, Fabiola Atzeni, Ruscitti, P., Berardicurti, O., Iacono, D., Pantano, I., Liakouli, V., Caso, F., Emmi, G., Grembiale, R. D., Cantatore, F. P., Atzeni, F., Perosa, F., Scarpa, R., Guggino, G., Ciccia, F., Barile, A., Cipriani, P., Giacomelli, R., Ruscitti P., Berardicurti O., Iacono D., Pantano I., Liakouli V., Caso F., Emmi G., Grembiale R.D., Cantatore F.P., Atzeni F., Perosa F., Scarpa R., Guggino G., Ciccia F., Barile A., Cipriani P., and Giacomelli R.
- Subjects
Lung Diseases ,myalgia ,Abdominal pain ,medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,Disease ,Severity of Illness Index ,Young Adult ,Adult onset Still's disease ,Internal medicine ,Case fatality rate ,medicine ,Humans ,Mortality ,Young adult ,Survival rate ,Aged ,Retrospective Studies ,Adult onset Still’s disease ,business.industry ,Mortality rate ,Lung disease ,Cohort ,lcsh:RC925-935 ,medicine.symptom ,business ,Still's Disease, Adult-Onset ,Biomarkers ,Research Article - Abstract
Background Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the disease comparing patients with LD and those without. Methods A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and predictive factors, and long-term outcomes. Patients with AOSD, who were included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort, were assessed. Results Out of 147 patients included in GIRRCS cohort, 18 (12.25%) patients were reported to be affected by LD, at the time of diagnosis of AOSD, who were characterised by older age, a higher prevalence of myalgia, of lymph node involvement, of pleuritis, and abdominal pain. Furthermore, patients with LD showed higher values of systemic score and ferritin. Among those clinical variables, older age and systemic score were also independently predictors of LD. Chest CT scans were also obtained, and the most common finding was the peripheral consolidations in 8 (44.4%) patients. Finally, a higher mortality rate, of 38.9%, was registered in patients with LD than others, since it was associated with a significant decreased survival rate. Conclusions The presence of LD could suggest an emergent cause of mortality in AOSD, as observed in juvenile counterpart recognising a further marker of severity and poor prognosis to be careful evaluated. Patients with LD were also characterised by some clinical features, higher values of systemic score and ferritin than the others, identifying a subset of patients mostly burdened by systemic signs and symptoms. Although specific designed future studies are needed to fully elucidate the significance of LD in AOSD, a more accurate evaluation and management of this feature could improve the long-term outcomes of these patients.
- Published
- 2020
32. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort
- Author
-
Roberto Giacomelli, Giacomo Emmi, Piero Ruscitti, Daniela Iacono, Francesco Caso, Francesco Ciccia, Fabiola Atzeni, Francesco Paolo Cantatore, Giuliana Guggino, Rosa Daniela Grembiale, Paola Di Benedetto, Ilenia Pantano, Federico Perosa, Paola Cipriani, Raffaele Scarpa, Di Benedetto, P., Cipriani, P., Iacono, D., Pantano, I., Caso, F., Emmi, G., Grembiale, R. D., Cantatore, F. P., Atzeni, F., Perosa, F., Scarpa, R., Guggino, G., Ciccia, F., Giacomelli, R., Ruscitti, P., Di Benedetto P., Cipriani P., Iacono D., Pantano I., Caso F., Emmi G., Grembiale R.D., Cantatore F.P., Atzeni F., Perosa F., Scarpa R., Guggino G., Ciccia F., Giacomelli R., and Ruscitti P.
- Subjects
0301 basic medicine ,myalgia ,Adult-Onset ,Male ,Predictive Value of Test ,Pathology and Laboratory Medicine ,Logistic regression ,Biochemistry ,Gastroenterology ,Cohort Studies ,Mathematical and Statistical Techniques ,0302 clinical medicine ,Medicine and Health Sciences ,Multidisciplinary ,biology ,Macrophage Activation Syndrome ,Statistics ,Middle Aged ,C-Reactive Proteins ,C-Reactive Protein ,Predictive value of tests ,Physical Sciences ,Cohort ,Regression Analysis ,Medicine ,Female ,medicine.symptom ,Still's Disease, Adult-Onset ,Research Article ,Cohort study ,Human ,Adult ,medicine.medical_specialty ,Patients ,Logistic Model ,Inflammatory Diseases ,Science ,Pain ,Research and Analysis Methods ,03 medical and health sciences ,Biomarkers ,Ferritins ,Humans ,Logistic Models ,Predictive Value of Tests ,ROC Curve ,Signs and Symptoms ,Diagnostic Medicine ,Internal medicine ,medicine ,Statistical Methods ,030203 arthritis & rheumatology ,Ferritin ,business.industry ,C-reactive protein ,Biology and Life Sciences ,Proteins ,Protein Complexes ,Myalgia ,Biomarker ,medicine.disease ,Still's Disease ,Health Care ,030104 developmental biology ,Macrophage activation syndrome ,Multivariate Analysis ,biology.protein ,Cohort Studie ,business ,Mathematics - Abstract
ObjectiveTo assess the predictive role of ferritin and C-reactive protein (CRP) on occurrence of macrophage activation syndrome (MAS) and mortality in patients with adult onset Still's disease (AOSD), a rare and severe disease, included in the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort.MethodsThe predictive role, at the time of diagnosis, of serum levels of ferritin and CRP on occurrence of MAS and mortality, was evaluated by logistic regression analyses and receiver-operating characteristic (ROC) curves were built to identify patients at high risk of MAS and mortality, respectively.ResultsIn assessed 147 patients with AOSD, levels of ferritin were predictive of MAS (OR: 1.971; P: 0.002; CI 95%: 1.280-3.035). The ROC curve showed that the best cut-off for ferritin was 1225 ng/ml in predicting MAS (sensitivity 88%; specificity 57%). Levels of CRP were predictive of mortality in these patients (OR: 2.155; P: 0.007; CI 95%: 1.228-3.783). The ROC curve showed that the best cut-off for CRP was 68.7 mg/L in predicting mortality (sensitivity 80%; specificity of 65%).ConclusionsWe reported the predictive role of ferritin and CRP on MAS and mortality, respectively, in a large cohort of patients with AOSD, identifying subsets at higher risk of poor prognosis. Considering that the analysis of CRP and ferritin is widely available, these results could be readily transferable into clinical practice, thus improving the management of patients with AOSD.
- Published
- 2020
33. Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A Case-Control Study
- Author
-
Rosa Daniela Grembiale, Giorgio Ammerata, Ludovico Abenavoli, Giovambattista De Sarro, Ignazio Olivieri, Daniele Mauro, Emilio Russo, Saverio Naty, Francesco Ursini, Salvatore D Angelo, Caterina Bruno, Ursini, F., D’Angelo, S., Russo, E., Ammerata, G., Abenavoli, L., Mauro, D., Bruno, C., Naty, S., Grembiale, R. D., Olivieri, I., De Sarro, G., Ursini F., D'Angelo S., Russo E., Ammerata G., Abenavoli L., Mauro D., Bruno C., Naty S., Grembiale R.D., Olivieri I., and De Sarro G.
- Subjects
Male ,medicine.medical_specialty ,endocrine system diseases ,Population ,Type 2 diabetes ,Logistic regression ,01 natural sciences ,Gastroenterology ,NO ,Arthritis, Rheumatoid ,03 medical and health sciences ,Diabetes mellitus type 2 ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,030212 general & internal medicine ,Prediabetes ,Rheumatoid arthritis ,education ,Complement C3 ,Complement system proteins ,Insulin resistance ,Aged ,Pharmacology ,education.field_of_study ,business.industry ,010401 analytical chemistry ,Case-control study ,nutritional and metabolic diseases ,General Medicine ,Middle Aged ,medicine.disease ,0104 chemical sciences ,Logistic Models ,Diabetes Mellitus, Type 2 ,ROC Curve ,complement system protein ,Case-Control Studies ,prediabete ,Biomarker (medicine) ,Female ,business ,Biomarkers - Abstract
Background: Recent evidence demonstrated a potential role of complement C3 as a candidate biomarker of cardiometabolic risk in the general population.Objective: Aim of the present study was to investigate the correlation between complement C3 levels and comorbid type 2 diabetes (T2DM) in rheumatoid arthritis (RA) patients.Methods: For the present study, 40 consecutive diabetic RA patients (RA/T2DM(+) group) and 80 consecutive RA patients without diabetes (RA/T2DM-group) were recruited.Results: Patients in the RA/T2DM(+) group were significantly older (p < 0.0001), had a longer RA duration (p < 0.0001) and higher disease activity (p = 0.006) compared to controls. Moreover, patients in the RA/T2DM(+) group had significantly higher levels of ESR (p < 0.0001), CRP (p < 0.0001) and complement C3 (p < 0.0001). A logistic regression model was built to ascertain the effect of selected variables (age, RA duration, BMI, ESR, C3, lnCRP, corticosteroid use) on the likelihood that patients have T2DM. Longer RA duration, ESR and C3 were associated with an increased likelihood of being classified as T2DM. Finally, we built ROC curves to evaluate the predictivity of RA duration, complement C3 and the combination of both variables on the likelihood of being diagnosed with T2DM. The area under the ROC curve was 0.79 (p < 0.0001) for RA duration, 0.71 (p < 0.0001) for complement C3 and 0.89 (p < 0.0001) for the combination of both variables.Conclusion: According to our data complement C3 levels can predict the presence of T2DM in RA patients.
- Published
- 2018
34. Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- Author
-
Salvatore D Angelo, Ignazio Olivieri, Emilio Russo, Giovambattista De Sarro, Christian Leporini, Rosario Peluso, F. Arturi, Rosa Daniela Grembiale, Giovanni Tripepi, Francesco Ursini, Leporini C., Russo E., D'Angelo S., Arturi F., Tripepi G., Peluso R., Grembiale R.D., Olivieri I., De Sarro G., Ursini F., Leporini, C., Russo, E., D'Angelo, S., Arturi, F., Tripepi, G., Peluso, R., Grembiale, R. D., Olivieri, I., De Sarro, G., and Ursini, F.
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,RA patient ,MEDLINE ,Type 2 diabetes ,Anti-TNFα ,Insulin resistance ,Meta-analysis ,RA patients ,Rheumatoid arthritis ,Type 2 diabete ,NO ,Arthritis, Rheumatoid ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Meta-analysi ,Rheumatoid arthriti ,030203 arthritis & rheumatology ,Pharmacology ,Tumor Necrosis Factor-alpha ,business.industry ,Insulin ,Antirheumatic Agent ,General Medicine ,medicine.disease ,Blockade ,Antirheumatic Agents ,Tumor necrosis factor alpha ,business ,Human - Abstract
Background: Rheumatoid Arthritis (RA) has been associated with insulin resistance (IR), a well-established pathophysiological feature of Type 2 Diabetes (T2DM). Inconsistent literature evidence suggests that IR could be ameliorated by biological medications targeting TNFα. Objective: The aim of this systematic review was to evaluate the effect of TNFα inhibitors (TNFi) on IR in RA patients. Methods: We performed a systematic review in order to identify the available data on the effect of anti- TNFα medications on IR in RA patients. For this purpose, MedLine (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL) and SCOPUS were searched up to December 2016. Results: The search strategy retrieved 209 individual records. Of these, only 12 articles were included in the systematic review. The pooled analysis under a random-effects model demonstrated a significant improvement of IR after treatment with TNFi quantified with the HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR), with a standardized difference in means (SDM) of -0.847 (95%CI: -1.278 - 0.417, p < 0.0001). Heterogeneity across studies was high (Q = 65.00 with df = 9, p < 0.001, I2 = 89.15%). Conclusion: Our meta-analysis suggests that TNFα blockade might improve IR in RA patients.
- Published
- 2018
35. Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study
- Author
-
Roberto Giacomelli, Gabriele Valentini, V. Liakouli, Francesco Paolo Cantatore, Giacomo Emmi, Elvira Favoino, Luca Navarini, C. Bruno, Rosa Daniela Grembiale, Marcella Prete, Antonella Afeltra, Federico Perosa, Antonella Riccardi, Lorenzo Emmi, Antonella Marcoccia, Ada Corrado, Prete, M, Favoino, E, Giacomelli, R, Afeltra, A, Cantatore, F P, Bruno, C, Corrado, A, Emmi, L, Emmi, G, Grembiale, R D, Navarini, L, Marcoccia, A, Liakouli, V, Riccardi, A, Valentini, G, and Perosa, F
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Benign condition ,Raynaud’s phenomenon ,Contact Lenses ,Lifestyle habit ,Work related ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Life Style ,Hematology ,Prosthesis implant ,business.industry ,Incidence (epidemiology) ,Incidence ,Case-control study ,Vasospasm ,Raynaud Disease ,General Medicine ,Hydrogen Peroxide ,Prostheses and Implants ,Middle Aged ,medicine.disease ,Environmental factor ,030104 developmental biology ,Logistic Models ,Contact lense ,Italy ,030220 oncology & carcinogenesis ,Case-Control Studies ,Cohort ,Multivariate Analysis ,Female ,Hydrogen peroxide-based compound ,Lifestyle habits ,business ,Disinfectants - Abstract
Raynaud's phenomenon (RP) is a clinical disorder characterized by recurrent, reversible episodes of digital vasospasm. RP can be classified as primary (pRP) or secondary, depending on whether it occurs as a benign condition (not disease-associated) or is associated with other diseases, mainly of the connective tissues. In both cases, it can be triggered by environmental factors, as indicated by the increased incidence of pRP episodes following exposure to cold, vibration injury or chemicals. The purpose of this prospective case-control study was to assess, in an Italian cohort of 132 pRP patients, the association of the phenomenon with demographic, lifestyle habits, environmental and work-related factors. Compared to healthy controls, pRP was found to be inversely associated with the use of contact lenses (OR = 0.4; p = 0.004) and of chlorous-based disinfectants (OR = 0.3; p
- Published
- 2019
36. Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study
- Author
-
Rosa Daniela Grembiale, Caterina Bruno, Luisa Costa, Francesca Desiati, Roberta Ramonda, Giuliana Gualberti, Cesare Tripolino, Alen Zabotti, Pierluigi Macchioni, Stefania Gasparini, Umberto di Luzio Paparatti, Carlo Salvarani, Niccolò Possemato, Rocco Merolla, Raffaella Aldigeri, I. Farina, Giovanni Ciancio, Fabio Massimo Perrotta, Antonio Marchesoni, Rita Maria D’Attino, Raffaele Scarpa, Paola Frallonardo, Marwin Gutierrez, Carlo Perricone, Marcello Govoni, Salvatore De Vita, Walter Grassi, Macchioni, P., Salvarani, C., Possemato, N., Gutierrez, M., Grassi, W., Gasparini, S., Perricone, C., Perrotta, F. M., Grembiale, R. D., Bruno, C., Tripolino, C., Govoni, M., Ciancio, G., Farina, I., Ramonda, R., Frallonardo, P., Desiati, F., Scarpa, R., Costa, L., Zabotti, A., De Vita, S., D'Attino, R. M., Gualberti, G., Merolla, R., Di Luzio Paparatti, U., Aldigeri, R., and Marchesoni, A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Fibromyalgia ,Immunology ,Enthesitis ,Fibromyalgia syndrome ,Psoriasis ,Psoriatic arthritis ,Ultrasonography ,Physical examination ,Psoriatic ,Enthesopathy ,Severity of Illness Index ,NO ,03 medical and health sciences ,0302 clinical medicine ,ULTRASONOGRAPHY ,Rheumatology ,Severity of illness ,FIBROMYALGIA SYNDROME ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Enthesiti ,ENTHESITIS ,Psoriasi ,030203 arthritis & rheumatology ,PSORIASIS ,medicine.diagnostic_test ,business.industry ,Arthritis ,Psoriatic arthriti ,Arthritis, Psoriatic ,Doppler ,PSORIATIC ARTHRITIS ,Ultrasonography, Doppler ,Middle Aged ,medicine.disease ,Enthesis ,Dermatology ,Cross-Sectional Studies ,Female ,medicine.symptom ,business - Abstract
Objective.The purpose of the ULISSE study was to evaluate the prevalence of clinical and ultrasonographic (US) entheseal involvement in patients with psoriatic arthritis (PsA), psoriasis, and fibromyalgia syndrome (FMS).Methods.In this cross-sectional multicenter study, patients with PsA and psoriasis (not taking systemic therapy) and FMS underwent a clinical evaluation of the entheses, and a B-mode and power Doppler examination of 6 pairs of entheses.Results.The study analyzed 140 patients with PsA, 51 with psoriasis, and 51 with FMS. Clinical and US examinations were performed in 1960 and 1680 entheses in the PsA group, and 714 and 612 entheses both in the psoriasis group and in the FMS group. In both per-patient and per-enthesis evaluation, the frequency of entheseal tenderness was higher in patients with FMS (92% of the patients and 46% of the entheses, compared with 66%/23% in the PsA group and 59%/18% in the psoriasis group). With US examination, signs of entheseal involvement were more frequent in both the per-patient and per-enthesis evaluation in PsA and psoriasis (about 90% of patients in both the PsA and psoriasis groups and 75% of patients in the FMS group had at least 1 site affected, and 54%, 41%, and 27% of the pairs of entheses in, respectively, PsA, psoriasis, and FMS patients showed at least 1 enthesis involved).Conclusion.The ULISSE study indicated that enthesitis is a common feature in patients with PsA, those with psoriasis, and in those with FMS if only clinical examination is used. US entheseal assessment showed findings more consistent with the 3 disorders.
- Published
- 2019
37. Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study
- Author
-
Piero Ruscitti, Serena Fasano, Francesco Paolo Cantatore, Luca Navarini, Daniela Iacono, Gabriele Valentini, Nicola Maruotti, Virginia D'Abrosca, Roberto Giacomelli, Rosa Daniela Grembiale, Antonella Afeltra, Ilenia Pantano, Domenico Paolo Emanuele Margiotta, Iacono, D., Fasano, S., Pantano, I., D'Abrosca, V., Ruscitti, P., Margiotta, D. P. E., Navarini, L., Maruotti, N., Grembiale, R. D., Cantatore, F. P., Afeltra, A., Giacomelli, R., and Valentini, G.
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Article Subject ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,Hydroxychloroquine ,Retrospective cohort study ,030204 cardiovascular system & hematology ,medicine.disease ,INCEPTION COHORT ,03 medical and health sciences ,0302 clinical medicine ,lcsh:RC666-701 ,Rheumatoid arthritis ,Internal medicine ,Cohort ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Low dose aspirin ,medicine.drug ,Research Article - Abstract
Objective. To investigate the role of acetylsalicylic acid (ASA) in reducing the incidence of cardiovascular (CV) events in an Italian multicentre rheumatoid arthritis (RA) inception cohort. Methods. The clinical charts of RA patients consecutively admitted to 4 Italian centres for their 1st visit from November 1, 2000, to December 31, 2015, and followed up till December 2016 were retrospectively investigated for the incidence of CV events. Patients were subdivided into two groups, namely, ASA- and non-ASA-treated groups. The Kaplan–Meier curve and log-rank test were used to investigate differences in event-free survival. Cox regression analysis was carried out to identify factors associated with CV event occurrence. Results. Seven hundred forty-six consecutive RA patients were enrolled and followed up for a median of 5.6 years (range 2.9–8.9 years). The incidence rate (IR) of CV events was 8/1000 person-years (p-ys) in the overall cohort. The IR of CV events was significantly lower in the ASA-treated group with respect to the non-ASA-treated group (IR 1.7 vs. 11.8/1000 p-ys; p=0.0002). The CV event-free rate was longer in ASA-treated patients than in non-ASA-treated patients (log-rank test 12.8; p=0.0003). At multivariable analysis, arterial hypertension (HR 9.3) and hypercholesterolemia (HR 2.8) resulted to be positive predictors and ASA (HR 0.09) and hydroxychloroquine (HCQ) (HR 0.22) to be negative predictors. Conclusion. The IR of CV events in our Italian multicentre cohort was lower than that reported in other European and non-European cohorts. Low-dose ASA may have a role in the primary prophylaxis of CV events in RA patients.
- Published
- 2019
38. Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study
- Author
-
Raffaele Scarpa, Francesco Paolo Cantatore, Licia Picciariello, Federico Perosa, Giulia Maria Destro Castaniti, Piero Ruscitti, Nicola Maruotti, Luca Navarini, Sara Bongiovanni, Domenico Paolo Emanuele Margiotta, Rosa Daniela Grembiale, Roberto Giacomelli, Giacomo Emmi, Antonella Afeltra, Daniela Iacono, Fabiola Atzeni, Paola Cipriani, Giuliana Guggino, Francesco Caso, Francesco Ciccia, Gerardo Di Scala, Vasiliki Liakouli, Ilenia Pantano, Ruscitti, P., Cipriani, P., Liakouli, V., Iacono, D., Pantano, I., Margiotta, D. P. E., Navarini, L., Destro Castaniti, G. M., Maruotti, N., Di Scala, G., Picciariello, L., Caso, F., Bongiovanni, S., Grembiale, R. D., Atzeni, F., Scarpa, R., Perosa, F., Emmi, G., Cantatore, F. P., Guggino, G., Afeltra, A., Ciccia, F., Giacomelli, R., Ruscitti P., Cipriani P., Liakouli V., Iacono D., Pantano I., Margiotta D.P.E., Navarini L., Destro Castaniti G.M., Maruotti N., Di Scala G., Picciariello L., Caso F., Bongiovanni S., Grembiale R.D., Atzeni F., Scarpa R., Perosa F., Emmi G., Cantatore F.P., Guggino G., Afeltra A., Ciccia F., and Giacomelli R.
- Subjects
0301 basic medicine ,Male ,Time Factors ,lcsh:Diseases of the musculoskeletal system ,Type 2 diabetes ,Comorbidity ,Arthritis, Rheumatoid ,0302 clinical medicine ,Prospective Studies ,Subclinical infection ,Aged, 80 and over ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,Age Factors ,Middle Aged ,Prognosis ,Cardiovascular disease ,Survival Rate ,Cardiovascular diseases ,Italy ,Rheumatoid arthritis ,Atherosclerosi ,Cohort ,Disease Progression ,Female ,Research Article ,Adult ,medicine.medical_specialty ,Remission ,Population ,03 medical and health sciences ,Young Adult ,Age Distribution ,Sex Factors ,Internal medicine ,medicine ,Humans ,Sex Distribution ,education ,Rheumatoid arthriti ,Aged ,030203 arthritis & rheumatology ,business.industry ,Atherosclerosis ,medicine.disease ,Rheumatology ,Settore MED/16 - Reumatologia ,030104 developmental biology ,Blood pressure ,lcsh:RC925-935 ,business ,Follow-Up Studies - Abstract
Background Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA. Methods From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the occurrence of subclinical and clinical atherosclerosis and possible predictive factors. McNemar test was employed to assess the changes in subclinical and clinical atherosclerosis, and regression analyses exploited the ORs for the occurrence of those comorbidities. Results We analysed 841 participants, mostly female (82.2%) and with median age of 60 years (range 21–90). The remission was achieved and maintained by 41.8% of participants during the follow-up. We observed an increased rate of subclinical atherosclerosis at the end of follow-up (139 vs 203 participants, p
- Published
- 2019
39. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis
- Author
-
Emilio Russo, Salvatore D'Angelo, Rosa Daniela Grembiale, F Bene, Costantino Pitzalis, Giovambattista De Sarro, Francesco Ursini, Myles Lewis, Daniele Mauro, Christian Leporini, Ignazio Olivieri, Ursini F., Leporini C., Bene F., D'Angelo S., Mauro D., Russo E., De Sarro G., Olivieri I., Pitzalis C., Lewis M., Grembiale R.D., Ursini, F., Leporini, C., Bene, F., D'Angelo, S., Mauro, D., Russo, E., De Sarro, G., Olivieri, I., Pitzalis, C., Lewis, M., and Grembiale, R. D.
- Subjects
Oncology ,medicine.medical_specialty ,Science ,MEDLINE ,Arthritis ,030204 cardiovascular system & hematology ,methotrexate ,Article ,law.invention ,NO ,Arthritis, Rheumatoid ,03 medical and health sciences ,cardiovascular events ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Endothelial dysfunction ,risk-factors ,endothelial function, rheumatoid arthritis ,030203 arthritis & rheumatology ,therapy ,Multidisciplinary ,dysfunction ,Tumor Necrosis Factor-alpha ,business.industry ,Endothelial Cells ,improves ,Publication bias ,medicine.disease ,3. Good health ,Treatment Outcome ,inflammation ,Meta-analysis ,Rheumatoid arthritis ,Physical therapy ,Medicine ,Body insulin sensitivity ,psoriatic-arthritis ,atherosclerosis ,business ,Cohort study - Abstract
Rheumatoid arthritis (RA) has been associated with endothelial dysfunction, a pathophysiological feature of atherosclerosis. Our aim was to determine whether TNF-α blockade has a beneficial effect on endothelial function in RA. We performed a systematic review with meta-analysis to evaluate the effect of anti-TNF-α agents on endothelial function in RA patients. MedLine, Cochrane CENTRAL and SCOPUS were searched up to March 2016. Inclusion criteria were: 1) randomised controlled trial (RCT), quasi-RCT, before-after cohort study; 2) including RA patients; 3) treatment with anti-TNF-α medications; 4) evaluating the change from baseline in endothelial function. The search strategy retrieved 180 records, of which 20 studies were included in the systematic review. Pooled analysis using a random-effects model demonstrated a significant improvement in endothelial function following anti-TNF-α treatment (SDM 0.987, 95%CI [0.64–1.33], p
- Published
- 2017
40. Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study
- Author
-
Salvatore D'Angelo, Rosa Daniela Grembiale, Giovambattista De Sarro, Emilio Russo, Daniele Mauro, Francesco Ursini, Giorgio Ammerata, Ludovico Abenavoli, Ignazio Olivieri, Alfonso Serrao, Ursini, F., Russo, E., Mauro, D., Abenavoli, L., Ammerata, G., Serrao, A., Grembiale, R. D., De Sarro, G., Olivieri, I., D'Angelo, S., Ursini F., Russo E., Mauro D., Abenavoli L., Ammerata G., Serrao A., Grembiale R.D., De Sarro G., Olivieri I., and D'angelo S.
- Subjects
nonalcoholic fatty liver disease ,medicine.medical_specialty ,Cross-sectional study ,Clinical Biochemistry ,Population ,hepatic steatosis index ,liver ultrasonography ,Biochemistry ,Gastroenterology ,NO ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Complement C3 ,Rheumatoid arthritis ,education ,030203 arthritis & rheumatology ,education.field_of_study ,Receiver operating characteristic ,business.industry ,Fatty liver ,nutritional and metabolic diseases ,General Medicine ,medicine.disease ,Endocrinology ,Biomarker (medicine) ,030211 gastroenterology & hepatology ,Steatosis ,business - Abstract
Background Recent evidence suggested a potential role of complement fraction C3 as a biomarker of non-alcoholic fatty liver disease (NAFLD) in the general population. Aim of the present study was to evaluate the performance of C3 for prediction of NAFLD in RA patients. Materials and methods For the present study, consecutive RA patients were recruited. NAFLD was diagnosed according to predefined ultrasonographic (US) criteria. For comparison, the hepatic steatosis index (HSI) was calculated. Results Out of 164 consecutive RA patients, 41 (25%) were diagnosed with NAFLD. The NAFLD group had a significant lower proportion of females (p = 0.04), higher BMI (p < 0.0001), C-reactive protein (p = 0.04), complement C3 (p = 0.001) and HSI (p = 0.003). In a logistic regression model, only male sex (OR 2.65, 95% CI: 1.08 - 6.50, p = 0.03), increasing BMI (OR 1.22, 95% CI: 1.02 – 1.46, p = 0.03) and complement C3 (OR 5.05, 95% CI: 1.06 - 23.93, p = 0.04) were associated with higher likelihood of being diagnosed with NAFLD. Finally, we built ROC curves for BMI, complement C3 and their combination for prediction of having NAFLD. The best cut-off for BMI was 28.5 kg/m2 and yielded a sensitivity of 66% and a specificity of 71%; the best cut-off for complement C3 was 1.23 g/l and yielded a sensitivity of 76% and a specificity of 64% for classification of NAFLD cases. Conclusions Our results provide preliminary evidence for a potential role of complement C3 as a surrogate biomarker of NAFLD in RA patients This article is protected by copyright. All rights reserved.
- Published
- 2017
41. Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives
- Author
-
Saverio Naty, Ignazio Olivieri, Rosa Daniela Grembiale, Francesco Ursini, Daniele Mauro, Pasqualina Sannino, Caterina Bruno, Salvatore D Angelo, Gaetano Barbagallo, Mauro D., Barbagallo G., D'Angelo S., Sannino P., Naty S., Bruno C., Olivieri I., Grembiale R.D., Ursini F., Mauro, D., Barbagallo, G., D'Angelo, S., Sannino, P., Naty, S., Bruno, C., Olivieri, I., Grembiale, R. D., and Ursini, F.
- Subjects
Vasculitis ,Central Nervous System ,Pathology ,medicine.medical_specialty ,Positron emission tomography ,Systemic lupus erythematosu ,Disease ,Behcet's disease ,Biochemistry ,NO ,Autoimmune Diseases ,03 medical and health sciences ,Epilepsy ,0302 clinical medicine ,Systemic lupus erythematosus ,Fluorodeoxyglucose F18 ,Drug Discovery ,medicine ,Humans ,Neuroinflammation ,Depression (differential diagnoses) ,030203 arthritis & rheumatology ,Pharmacology ,Behcet’s disease ,Brain ,Central nervous system ,medicine.diagnostic_test ,business.industry ,Organic Chemistry ,Magnetic resonance imaging ,medicine.disease ,Positron-Emission Tomography ,Molecular Medicine ,Molecular imaging ,business ,030217 neurology & neurosurgery - Abstract
In the last years, an increasing interest in molecular imaging has been raised by the extending potential of positron emission tomography [PET]. The role of PET imaging, originally confined to the oncology setting, is continuously extending thanks to the development of novel radiopharmaceutical and to the implementation of hybrid imaging techniques, where PET scans are combined with computed tomography [CT] or magnetic resonance imaging[MRI] in order to improve spatial resolution. Early preclinical studies suggested that 18F–FDG PET can detect neuroinflammation; new developing radiopharmaceuticals targeting more specifically inflammation-related molecules are moving in this direction. Neurological involvement is a distinct feature of various systemic autoimmune diseases, i.e. Systemic Lupus Erythematosus [SLE] or Behcet’s disease [BD]. Although MRI is largely considered the gold-standard imaging technique for the detection of Central Nervous System [CNS] involvement in these disorders. Several patients complain of neuropsychiatric symptoms [headache, epilepsy, anxiety or depression] in the absence of any significant MRI finding; in such patients the diagnosis relies mainly on clinical examination and often the role of the disease process versus iatrogenic or reactive forms is doubtful. The aim of this review is to explore the state-of-the-art for the role of PET imaging in CNS involvement in systemic rheumatic diseases. In addition, we explore the potential role of emerging radiopharmaceutical and their possible application in aiding the diagnosis of CNS involvement in systemic autoimmune diseases.
- Published
- 2016
42. Use of sonoelastography to evaluate texture modifications of mozzarella di bufala campana d.O.p. during storage at different temperatures
- Author
-
Antonio Di Loria, Domenico Britti, Nicola Costanzo, A. Santoro, Eleonora Sarno, Rosa Daniela Grembiale, Federico Capuano, Costanzo, N., Santoro, A. M. L., Sarno, E., Di Loria, A., Grembiale, R. D., Britti, D., and Capuano, F.
- Subjects
Materials science ,Significant difference ,Organoleptic ,Temperature ,Sonoelastography ,Mozzarella di Bufala Campana D.O.P ,White colour ,Food science ,Texture (crystalline) ,Texture modifications ,Mozzarella cheese ,Food Science ,High humidity - Abstract
Mozzarella cheese from buffalo milk is a fresh, stringy-textured dairy product, exhibiting a porcelain white colour, a smooth, bright, and humid surface, an extremely thin rind and delicate taste. The high humidity typical of this cheese, reduces its shelf-life and it is cause of dramatic organoleptic changes during storage. In this study we tested sonoelastography to evaluate texture changes of mozzarella cheese from buffalo milk during storage. Cheeses form local market produced in the same condition were divided in three batches and stored in different conditions: the first (B1) was stored in preserving liquid at room temperature (20°C); the second (B2) was stored without preserving liquid at 4°C; and the third (B3) was stored at 4°C in preserving liquid. In B1 sonoelastography showed a reduction of the hardness and stiffness of rind, while in B2 inelastic tissue increased its thickness. Best results were obtained in B3, where no significant difference was evidenced during storage.
- Published
- 2015
43. Improvement in insulin resistance after short-term treatment with abatacept: Case report and short review
- Author
-
Daniele Mauro, Denis Gagliardi, Rosa Daniela Grembiale, Francesco Ursini, Saverio Naty, Ursini F., Mauro D., Naty S., Gagliardi D., Grembiale R.D., Ursini, F., Mauro, D., Naty, S., Gagliardi, D., and Grembiale, R. D.
- Subjects
musculoskeletal diseases ,Immunoconjugates ,Time Factors ,T-Lymphocytes ,Arthritis ,Adipose tissue ,Inflammation ,Type 2 diabetes ,NO ,Arthritis, Rheumatoid ,Abatacept ,Insulin resistance ,Rheumatology ,CD28 Antigens ,Tcells ,Medicine ,Humans ,Rheumatoid arthritis ,Rheumatoid arthriti ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Glucose ,Treatment Outcome ,Adipose Tissue ,Antirheumatic Agents ,Immunology ,B7-1 Antigen ,Female ,Metabolic syndrome ,medicine.symptom ,Insulin Resistance ,business ,medicine.drug - Abstract
Insulin resistance, a key feature of type 2 diabetes, is an independent risk factor for developing cardiovascular diseases (CVD), and represents the core of metabolic syndrome (MetS). Actually, an intriguing correlation between MetS and inflammation associated with rheumatoid arthritis (RA) is largely accepted but not yet completely clarified in detail. Recently, the therapeutic arsenal against RA has been enriched of abatacept, a fusion protein (CTLA4 immunoglobulin) designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Here, we report a case of dramatic improvement in insulin resistance, estimated with the surrogate measure HOMA-IR, after treatment with abatacept. Lastly, we shortly review the preclinical evidences supporting a possible role of T lymphocytes in rheumatoid arthritis-associated insulin resistance and how abatacept could improve glucose metabolism by suppressing adipose tissue infiltrating cells. © Clinical Rheumatology 2012.
- Published
- 2012
44. Effects of transfoming growth factor-beta and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells
- Author
-
D. Fratto, Girolamo Pelaia, Rosa Daniela Grembiale, Francesco Costanzo, Rosario Maselli, Giovanni Cuda, Pierosandro Tagliaferri, Alessandro Vatrella, Serafino A. Marsico, Pelaia, G., Cuda, G., Vatrella, Alessandro, Fratto, D., Grembiale, R. D., Tagliaferri, P., Maselli, R., Costanzo, F. S., and Marsico, S. A.
- Subjects
Pulmonary and Respiratory Medicine ,MAPK/ERK pathway ,Programmed cell death ,budesonide ,Pyridines ,p38 mitogen-activated protein kinases ,Administration, Topical ,Clinical Biochemistry ,Anti-Inflammatory Agents ,Bronchi ,Apoptosis ,airway epithelial cell ,chemistry.chemical_compound ,Transforming Growth Factor beta ,Humans ,Propidium iodide ,Enzyme Inhibitors ,Phosphorylation ,tgf-beta ,MAPK ,Molecular Biology ,Glucocorticoids ,Cells, Cultured ,Anthracenes ,Flavonoids ,biology ,Kinase ,Caspase 3 ,Imidazoles ,Epithelial Cells ,Cell Biology ,Transforming growth factor beta ,Cell biology ,Enzyme Activation ,chemistry ,Mitogen-activated protein kinase ,Caspases ,biology.protein ,Signal transduction ,Mitogen-Activated Protein Kinases ,Signal Transduction - Abstract
Airway epithelial cells play a central role in the inflammatory, apoptotic, and remodeling processes associated with asthma. Within this context, a key function is exerted by transforming growth factor-beta (TGF-beta), whose biological effects are mediated at least in part by mitogen-activated protein kinases (MAPKs). The aim of our study was to investigate, in primary cultures of human bronchial epithelial cells (HBEC), the effects of TGF-beta (10 ng/ml) on both MAPK activation and apoptosis, in the presence or absence of a pretreatment with budesonide (10-8 M). MAPK activation was detected by Western blotting, using anti-phospho-MAPK monoclonal antibodies, which specifically recognize the phosphorylated, active forms of these enzymes. Apoptosis was assayed by caspase-3 activation and fluorescence microscopy, using annexin-V (An-V) and propidium iodide (PI) as markers of cell death. Our results show that TGF-beta induced a marked ( reverse similar 9-fold) increase in p38 MAPK phosphorylation, and also dramatically enhanced cell death, which was completely prevented by specific MAPK inhibitors. Both MAPK activation and apoptosis were effectively inhibited by budesonide (BUD), thereby suggesting that the powerful antiapoptotic action of inhaled glucocorticoids may be very important for their protective role against epithelial injury, which represents a key pathogenic event in asthma.
- Published
- 2003
45. Snail ingestion and asthma
- Author
-
R. D. Grembiale, Sa Marsico, C. M. E. Tranfa, G. Pelaia, S. Naty, Grembiale, R. D., Naty, S., Pelaia, G., Tranfa, Carmelindo Mario Enrico, and Marsico, S. A.
- Subjects
Adult ,Male ,Allergy ,Immunology ,Snails ,Cross reactions ,Snail ,Biology ,Middle Aged ,medicine.disease ,Asthma ,Atopy ,Food allergy ,biology.animal ,medicine ,Immunology and Allergy ,Ingestion ,Animals ,Humans ,Female ,Child ,Food Hypersensitivity - Published
- 1996
46. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients.
- Author
-
Sciacqua A, Perticone M, Miceli S, Laino I, Tassone EJ, Grembiale RD, Andreozzi F, Sesti G, and Perticone F
- Subjects
- Acetylcholine pharmacology, Adult, Atherosclerosis diagnosis, Atherosclerosis epidemiology, Biomarkers, Cross-Sectional Studies, Dose-Response Relationship, Drug, Early Diagnosis, Endothelium, Vascular drug effects, Fatty Liver diagnostic imaging, Female, Humans, Hypertension complications, Insulin Resistance, Italy epidemiology, Liver diagnostic imaging, Male, Middle Aged, Nitroprusside pharmacology, Plethysmography, Risk Factors, Ultrasonography, Vasodilation drug effects, Vasodilator Agents pharmacology, Atherosclerosis etiology, Endothelium, Vascular physiopathology, Fatty Liver etiology, Hypertension physiopathology
- Abstract
Background and Aims: Non-alcoholic fatty liver disease, characterized by insulin resistance, has been correlated with several clinical and pathological manifestations, such as intima-media thickness. At present, no data are available regarding endothelial dysfunction, the first step in atherosclerosis, and non-alcoholic fatty liver disease. The aim of this study was to test a possible association between non-alcoholic fatty liver disease and endothelium-dependent vasodilation in a group of hypertensive patients., Methods and Results: A total of 40 never-treated uncomplicated hypertensive outpatients were enrolled. Patients underwent a complete clinical and biochemical work-up including ultrasonographic scanning to detect liver steatosis. Insulin sensitivity was estimated by using the homeostasis model assessment (HOMA) index. Endothelial function was assessed by strain-gauge plethysmography during intra-arterial infusion of increasing doses of acetylcholine and sodium nitroprusside. Endothelium-dependent vasodilation was significantly reduced in hypertensive patients with liver steatosis in comparison with those without. Statistical analysis demonstrated that the HOMA index was the strongest predictor of both endothelium-dependent vasodilation and liver steatosis. In particular, one point of HOMA accounts for 37.9% of forearm blood flow variation, and increases the risk of liver steatosis by 86.4%., Conclusion: Our data demonstrate that hypertensive patients with liver steatosis have a reduced endothelium-dependent vasodilation and highest insulin resistance. In keeping with this, it is possible to hypothesize that liver steatosis may be considered a marker of vascular damage in essential hypertension., (Copyright © 2009 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
47. Efficacy and safety of duloxetine in fibromyalgia.
- Author
-
Ursini F, Pipicelli G, and Grembiale RD
- Subjects
- Antidepressive Agents adverse effects, Clinical Trials as Topic, Duloxetine Hydrochloride, Humans, Thiophenes adverse effects, Antidepressive Agents therapeutic use, Fibromyalgia drug therapy, Thiophenes therapeutic use
- Abstract
Fibromyalgia is a chronic disorder of uncertain aetiology, more common in women than in man, characterized by widespread pain, muscle tenderness and decreased pain threshold to pressure and other stimuli. The pathophysiology of fibromyalgia is still unknown, but some evidences suggest that abnormalities in central monoaminergic transmission might play an important role. These abnormalities include dysfunction in both serotonin (5-HT) and norepinephrine (NE) systems. In addition, fibromyalgia frequently presents in comorbidity with depression and anxiety disorders. On these basis antidepressants are the most widely studied drugs and, probably the most effective therapy of fibromyalgia. Until now amitriptyline, a tricyclic antidepressant, was considered the most effective, with some evidence of efficacy for other antidepressant such as the SSRI fluoxetine and sertraline. Here we review the efficacy and safety of duloxetine, a SNRI antidepressant, in the management of fibromyalgia.
- Published
- 2010
48. Oxidative stress and lung diseases.
- Author
-
Maselli R, Grembiale RD, Pelaia G, and Cuda G
- Subjects
- Humans, Lung Diseases metabolism, Mitogen-Activated Protein Kinase Kinases physiology, Oxidative Stress physiology, Signal Transduction physiology
- Abstract
Several different lung diseases are characterized by an oxidant/antioxidant imbalance, which is a major cause of cell damage. Oxidative stress activates a complex network of intracellular signal transduction pathways involved in the regulation of transcription factors such as nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1). Within this context, a key role is played by mitogen-activated protein kinases (MAPK), which are highly expressed by pulmonary endothelial and airway epithelial cells. By exposing these cell lines to oxidant agents, our group has shown that oxidative stress leads to a significant MAPK activation, which can be effectively inhibited by corticosteroids. We believe that studies such as ours may contribute to further elucidate the molecular events underlying the therapeutic action of these drugs in many respiratory disorders caused by oxidative/proinflammatory pathogenic mechanisms. In addition, our findings may help to unveil new anti-oxidant treatments based on MAPK modulation.
- Published
- 2002
49. Bronchial asthma induced by an antithyroid drug.
- Author
-
Grembiale RD, Naty S, Iorio C, Crispino N, Pelaia G, and Tranfa CM
- Subjects
- Aged, Female, Humans, Antithyroid Agents adverse effects, Asthma chemically induced, Methimazole adverse effects
- Abstract
We report the case of a 67-year-old woman who suffered from a severe asthma exacerbation as a consequence of an antithyroid drug treatment prescribed for her multinodular, hyperfunctioning goiter. Asthma symptoms were associated with a very significant increase in the number of eosinophils, detected in both blood and induced sputum.
- Published
- 2001
- Full Text
- View/download PDF
50. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness.
- Author
-
Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, and Marsico SA
- Subjects
- Adolescent, Adult, Allergens administration & dosage, Analysis of Variance, Bronchial Hyperreactivity diagnosis, Bronchial Hyperreactivity physiopathology, Child, Double-Blind Method, Female, Humans, Immunoglobulin E blood, Immunotherapy statistics & numerical data, Male, Respiratory Function Tests methods, Respiratory Function Tests statistics & numerical data, Rhinitis, Allergic, Perennial diagnosis, Rhinitis, Allergic, Perennial physiopathology, Statistics, Nonparametric, Asthma physiopathology, Bronchial Hyperreactivity therapy, Immunotherapy methods, Rhinitis, Allergic, Perennial therapy
- Abstract
Allergic rhinitis can be associated with bronchial hyperresponsiveness (BHR), and carries an increased risk for the development of asthma. The aim of this study was to evaluate the ability of specific immunotherapy (SIT) to reduce the progression of allergic rhinitis to asthma and prevent the associated increase in BHR. Forty-four subjects monosensitized to Dermatophagoides pteronyssinus, with perennial rhinitis and BHR to methacholine, were randomly assigned to receive SIT or placebo in a double-blind study conducted over a period of 2 yr. After 1 yr of treatment, a 2.88-fold increase in the provocative dose of methacholine producing a 20% decrease in FEV(1) (PD(20)FEV(1)) was recorded in the SIT-treated group (95% confidence interval [CI]: 3.98- to 2.09-fold; p < 0.001), with a further increase to fourfold at the end of Year 2 (95% CI: 2.9- to 5.7-fold; p < 0.001). At the end of the study, the methacholine PD(20)FEV(1) was within the normal range in 50% of treated subjects (p < 0.0001), and was significantly higher in this group than in the group receiving placebo (p < 0.0001). In contrast, no changes in methacholine PD(20)FEV(1) were found in the placebo group throughout the study. Although 9% of subjects given placebo developed asthma, none of those treated with SIT did. This study suggests that SIT, when administered to carefully selected, monosensitized patients with perennial allergic rhinitis, reduces airway responsiveness in subjects with rhinitis, and may be an appropriate prophylactic treatment for rhinitic patients with hyperreactive airways.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.